CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $12.78B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.15: safe zone
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.78BUSDvs all stocks (USD)
Trailing P/E
30.52xvs Medical Instruments & Supplies peers
Revenue (TTM)
4.10BUSDvs all stocks (USD)
Profit Margin
10.50%vs Medical Instruments & Supplies peers
Beta
1.67xvs all stocks
52-Week Change
-7.52%vs all stocks
Market Capitalization
12.78BUSDvs all stocks (USD)
Enterprise Value
11.84BUSDvs all stocks (USD)
Trailing P/E
30.52xvs Medical Instruments & Supplies peers
Forward P/E
14.66xvs Medical Instruments & Supplies peers
PEG Ratio
1.25xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
3.17xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
3.13xvs Medical Instruments & Supplies peers
Enterprise to Revenue
2.89xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
13.44xvs Medical Instruments & Supplies peers
Gross Margin
70.82%vs Medical Instruments & Supplies peers
Profit Margin
10.50%vs Medical Instruments & Supplies peers
Operating Margin
15.47%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
7.23%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
10.82%vs Medical Instruments & Supplies peers
Revenue (TTM)
4.10BUSDvs all stocks (USD)
Revenue per Share (TTM)
56.88USDUpdated Jul 17, 2026Quarterly Revenue Growth
6.20%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
2.86BUSDvs all stocks (USD)
EBITDA (TTM)
943.47MUSDvs all stocks (USD)
Net Income (TTM)
429.89MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.00%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
691.59MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
532.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Instruments & Supplies peers
Revenue
4.03BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.32BUSDFY2025 · Dec 31, 2025Gross Profit
2.71BUSDFY2025 · Dec 31, 2025Operating Income
585.31MUSDvs all stocks (USD)
Pre-tax Income
585.29MUSDFY2025 · Dec 31, 2025Income Tax Expense
174.94MUSDFY2025 · Dec 31, 2025Net Income
410.35MUSDFY2025 · Dec 31, 2025EBIT
585.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
862.30MUSDFY2025 · Dec 31, 2025Research & Development
369.91MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.76BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
5.66USDFY2025 · Dec 31, 2025EPS (Diluted)
5.65USDFY2025 · Dec 31, 2025Basic Shares Outstanding
72.54MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
72.54MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
410.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
698.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
596.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.10BUSDFY2025 · Dec 31, 2025Income Tax Paid
134.75MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
410.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
237.44MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
33.09MUSDFY2025 · Dec 31, 2025Stock-based Compensation
185.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
77.43MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-139.91MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.33MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-110.95MUSDFY2025 · Dec 31, 2025Capital Expenditures
-102.44MUSDFY2025 · Dec 31, 2025Net Acquisitions
-10.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-112.44MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-465.94MUSDFY2025 · Dec 31, 2025Other Financing Charges
-20.39MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-464.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
71.62MSharesUpdated Jul 17, 2026Float Shares
67.02MSharesUpdated Jul 17, 2026Shares Short
4.68MSharesUpdated Jul 17, 2026Short Ratio
4.39daysvs all stocks
Short % of Shares Outstanding
7.46%vs all stocks
% Held by Insiders
6.82%vs all stocks
% Held by Institutions
100.82%vs all stocks
Total Cash (MRQ)
1.06BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
14.80USDUpdated Jul 17, 2026Total Debt (MRQ)
116.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0280xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
1.39xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
57.94USDUpdated Jul 17, 2026Total Assets
6.23BUSDvs all stocks (USD)
Total Current Assets
2.62BUSDFY2025 · Dec 31, 2025Total Liabilities
2.18BUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.62BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
264.53MUSDFY2025 · Dec 31, 2025Total Current Liabilities
1.92BUSDFY2025 · Dec 31, 2025Cash
770.05MUSDFY2025 · Dec 31, 2025Cash Equivalents
324.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.09BUSDFY2025 · Dec 31, 2025Accounts Receivable
1.10BUSDFY2025 · Dec 31, 2025Inventory
226.34MUSDFY2025 · Dec 31, 2025Accounts Payable
121.45MUSDFY2025 · Dec 31, 2025Short-term Debt
31.94MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.26BUSDFY2025 · Dec 31, 2025Long-term Debt
82.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
113.82MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
2.46BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.05BUSDvs all stocks (USD)
52-Week Low
122.00USDUpdated Jul 17, 202652-Week High
208.31USDUpdated Jul 17, 202652-Week Change
-7.52%vs all stocks
Beta
1.67xvs all stocks
50-Day MA
171.58USDUpdated Jul 17, 2026200-Day MA
163.76USDUpdated Jul 17, 2026Avg 10-Day Volume
869.77KSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.01MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
5.94USDUpdated Jul 17, 2026Other Income / Expense
-16.07MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.15: safe zoneNotable
Altman Z-Score: 5.15
High earnings qualityNotable
Earnings Quality Score: 1.36
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $12.78B, above the global median of $1.15BNotable
Market cap (USD): 12,777,390,038Global Median: 1,146,734,693.424
Revenue is $4.1B, above the global median of $520.53MNotable
Revenue (USD): 4,095,789,056Global Median: 520,528,949.311
Levered free cash flow is $532.95M, above the global median of $16.24MNotable
Levered free cash flow (USD): 532,954,624Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
BorgWarner Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Enlight Renewable Energy Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
S-Oil Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
Tata Power Company Limited
Tier 1ProductionThroughput-Bound ConversionFlowRule
Guangzhou Automobile Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Tata Motors Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
IonQ, Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingInterface
Crane NXT Co.
Tier 1ProductionThroughput-Bound ConversionFlowRule
OmniVision Integrated Circuits Group, Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Mueller Industries Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Novo Nordisk A/S
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedReceivables Heavy and GrowingRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedRevenue Growing With Receivables GrowingWorking Capital PatternIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
XPEL, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin